See the DrugPatentWatch profile for lipitor

Based on the information available, it is challenging to definitively conclude whether Lipitor's marketing efforts directly boosted its post-patent sales. However, it is known that Lipitor, a cholesterol-lowering drug manufactured by Pfizer, faced generic competition after its patent expiration in 2011 [1].

Post-patent, Lipitor's sales decreased significantly due to the introduction of generic alternatives [1]. This suggests that while Pfizer's marketing efforts might have helped maintain Lipitor's market share during its patent-protected period, they did not prevent a decline in sales once generic versions became available.

It is important to note that the pharmaceutical industry often relies on marketing efforts to differentiate their products, even when generics are available [2]. These efforts can include direct-to-consumer advertising, physician education, and patient support programs [2]. However, the impact of these marketing efforts on post-patent sales is not always clear and may vary depending on a range of factors, including the competitive landscape, the perceived benefits of the branded drug, and the price of generic alternatives [2].

In conclusion, while Lipitor's marketing efforts may have contributed to its success during its patent-protected period, the available information does not provide clear evidence that these efforts significantly boosted Lipitor's post-patent sales.

Sources:
[1] "Lipitor (Atorvastatin)". DrugPatentWatch.com. Accessed on February 22, 2023. <https://www.drugpatentwatch.com/drugs/lipitor>.
[2] "Pharmaceutical Marketing: Current Trends and Future Directions". National Center for Biotechnology Information. Accessed on February 22, 2023. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141625/>.